• Explore /
  • Poster
  • / A phase I/II multicenter study of ABI-009 (<em>nab</em>-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.

A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.

Abstract Poster

Authors

null

Sunil Sharma

University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Sunil Sharma , Carlos Roberto Becerra , Marc Ryan Matrana , Angela Tatiana Alistar , E. Gabriela Chiorean , Anita Nagypal Schmid , Berta Grigorian , Shihe Hou , Neil Desai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT03439462

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr TPS730)

DOI

10.1200/JCO.2019.37.4_suppl.TPS730

Abstract #

TPS730

Poster Bd #

Q15

Abstract Disclosures

Similar Posters

First Author: Meredith Pelster

First Author: Gemma Bruera

First Author: Helena Verdaguer

First Author: Mark H. O'Hara